Scarica l'app Stockscreener
25.09
0.04%
0.01
Pre-mercato:
26.00
0.91
+3.63%
Damora Therapeutics Inc Borsa (DMRA) Ultime notizie
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - marketbeat.com
Damora Therapeutics, Inc. Common Stock (DMRA) 10K Form and Latest SEC Filings 2026 - MarketBeat
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Price Up 8.5%What's Next? - MarketBeat
Did Damora’s New Biopharma Heavyweight Leadership Just Reshape Damora Therapeutics' (DMRA) Investment Narrative? - Sahm
Damora Therapeutics, Inc. Common Stock (DMRA) Earnings Date and Reports 2026 - MarketBeat
Damora Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
DMRA Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - bitget.com
New Damora CEO gets 2 million-share hiring package under Nasdaq rule - Stock Titan
ETFs Investing in Damora Therapeutics, Inc. Stocks - TradingView
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Short Interest Update - marketbeat.com
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Average Rating of "Moderate Buy" by Analysts - marketbeat.com
DMRA (Damora Therapeutics) PB Ratio : (As of Mar. 28, 2026) - GuruFocus
DMRA PE Ratio & Valuation, Is DMRA Overvalued - Intellectia AI
DMRA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Trading Down 9.6%Time to Sell? - MarketBeat
Damora Therapeutics Inc (DMRA) Stock Earnings Transcripts - GuruFocus
Damora Therapeutics Inc (DMRA) Stock Price & 30 Year Financial Data - GuruFocus
This Vertiv Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
Damora Therapeutics (DMRA) grants 250,000 stock options to General Counsel - Stock Titan
Damora Therapeutics director granted 37,313 options | DMRA Insider Trading - Stock Titan
Damora Therapeutics (DMRA) director receives 37,313-share stock option grant - Stock Titan
Damora Therapeutics (DMRA) insiders receive 37,313-share option grant via Fairmount - Stock Titan
Damora Therapeutics (DMRA) director option grant tied to Fairmount funds - stocktitan.net
Damora Therapeutics (DMRA) director awarded 37,313 stock options - Stock Titan
Damora Therapeutics (DMRA) director files Form 3 initial ownership report - Stock Titan
Damora Therapeutics (NASDAQ: DMRA) director Michael Landsittel files Form 3 - Stock Titan
Damora Therapeutics Inc (DMRA) DCF Valuation - GuruFocus
Damora Therapeutics Inc (DMRA) Insider Trading Activity | Apple Insider Buys and Sells - GuruFocus
Evercore ISI Group Initiates Coverage on DMRA with 'Outperform' - GuruFocus
Evercore ISI initiates Damora Therapeutics stock with outperform By Investing.com - Investing.com India
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Earns Outperform Rating from Analysts at Evercore - marketbeat.com
Evercore ISI initiates Damora Therapeutics stock with outperform - Investing.com
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):